Rank-Rankl-Opg Axis in Multiple Sclerosis: The Contribution of Placenta
Authors:
- Sofia PassapontiSPSofia Passaponti
- Leonardo ErminiLELeonardo Ermini
- Giulia AcconciGAGiulia Acconci
- Filiberto Maria SeveriFSFiliberto Maria Severi
- Roberta RomagnoliRRRoberta Romagnoli
- Santina CutrupiSCSantina Cutrupi
- Marinella ClericoMCMarinella Clerico
- Gisella GuerreraGGGisella Guerrera
- Francesca IettaFIFrancesca Ietta
Open Access
Abstract
Women with multiple sclerosis (MS) can safely become pregnant and give birth, with no side effects or impediments. Pregnancy is generally accepted as a period of well-being in which relapses have a softer evolution, particularly in the third trimester. Herein, we hypothesized that the placenta, via its “secretome”, could contribute to the recognized beneficial effects of pregnancy on MS activity. We focused on a well-known receptor/ligand/decoy receptor system, such as the one composed by the receptor activator of nuclear factor-kB (RANK), its ligand (RANKL), and the decoy receptor osteoprotegerin (OPG), which have never been investigated in an integrated way in MS, pregnancy, and placenta. We reported that pregnancy at the term of gestation influences the balance between circulating RANKL and its endogenous inhibitor OPG in MS women. We demonstrated that the placenta at term is an invaluable source of homodimeric OPG. By functional studies on astrocytes, we showed that placental OPG suppresses the mRNA expression of the CCL20, a chemokine responsible for Th17 cell recruitment. We propose placental OPG as a crucial molecule for the recognized beneficial effect of late pregnancy on MS and its potential utility for the development of new and more effective therapeutic approaches.Keywords
Funding Information
- Associazione Italiana Sclerosi Multipla (2019/PR-Single/009)
This publication has 60 references indexed in Scilit:
- Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumabNature Reviews Drug Discovery, 2012
- Placenta suppresses experimental autoimmune hypophysitis through soluble TNF receptor 1Journal of Autoimmunity, 2012
- Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patientsArthritis Research & Therapy, 2011
- Functional Dissection of Osteoprotegerin and Its Interaction with Receptor Activator of NF-κB LigandJournal of Biological Chemistry, 2005
- Maternal plasma osteoprotegerin concentration in normal pregnancyAmerican Journal of Obstetrics and Gynecology, 2005
- Fetal Cell‐Free Nucleic Acids in the Maternal Circulation: New Clinical ApplicationsAnnals of the New York Academy of Sciences, 2004
- Immunological Study on Circulating Murine Osteoprotegerin/Osteoclastogenesis Inhibitory Factor (OPG/OCIF): Possible Role of OPG/OCIF in the Prevention of Osteoporosis in PregnancyBiochemical and Biophysical Research Communications, 2001
- Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFβ3Journal of Clinical Investigation, 2000
- Immunological Characterization of Circulating Osteoprotegerin/Osteoclastogenesis Inhibitory Factor: Increased Serum Concentrations in Postmenopausal Women with OsteoporosisJournal of Bone and Mineral Research, 1999
- Characterization of the Intracellular Domain of Receptor Activator of NF-κB (RANK)Journal of Biological Chemistry, 1998